宫颈癌是世界上女性中第四常见的癌症，通常在35至44岁之间被诊断出。尽管自2000年以来死亡率每年下降1％，但晚期患者的5年生存率仍低于20％。这突显了继续研究宫颈癌细胞存活因素并确定新的预后标志的紧迫性。在《生殖科学》期刊的这一期中，杨等人通过分析TCGA数据库中的200个与缺氧相关的基因将缺氧亚型进行分层，观察患者总体生存率、缺氧、转录组、基因组和免疫学特征在这些缺氧子型之间的变化，并创建了一个成功预测患者临床结果和对免疫治疗响应的缺氧得分。同时，还确定了一个与侵袭性宫颈癌表型相关的缺氧介质（S100A2）。我们回顾了关于S100A2和缺氧介导的多药耐药性的类似研究，并强调了这项研究所增加的价值。未来的工作可以集中于揭示S100A2与免疫治疗抵抗之间的直接联系。© 2023. 作者。

Cervical cancer is the fourth most common cancer in women worldwide and typically diagnosed between the ages of 35 and 44. Despite the death rate declining 1% each year since the 2000s, the 5-year survival of late stage remains lower than 20%. This emphasizes the urgency to keep exploring cervical cancer cell survival factors and identifying new prognostic markers. In this issue of Reproductive Sciences, Yang et al. stratified hypoxia subtype by analyzing 200 hypoxia-related genes in TCGA database and observed patient overall survival, hypoxic, transcriptome, genomics, and immunological characteristics vary among these hypoxia subtypes and created a hypoxia score which successfully stratified patient by predicting clinical outcomes and response to immunotherapy. Simultaneously, a hypoxia mediator (S100A2) associated with an aggressive cervical cancer phenotype is identified. We reviewed similar work on S100A2 and hypoxia-mediated multidrug resistance and highlighted the values added by this study. Future work could focus on unraveling the direct link between S100A2 and immunotherapy resistance.© 2023. The Author(s).